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Abstract
Exploration of treatment effect heterogeneity (TEH) is an increasingly important
aspect of modern statistical analysis for stratified medicine in randomised controlled
trials (RCTs) as we start to gather more information on trial participants and wish
to maximise the opportunities for learning from data. However, the analyst should
refrain from including a large number of variables in a treatment interaction discovery
stage. Because doing so can significantly dilute the power to detect any true outcome-
predictive interactions between treatments and covariates. Current guidance is limited
and mainly relies on the use of unsupervised learning methods, such as hierarchical
clustering or principal components analysis, to reduce the dimension of the variable
space prior to interaction tests. In this article we show that outcome-driven dimension
reduction, i.e. supervised variable selection, can maintain power without inflating the
type-I error or false-positive rate. We provide theoretical and applied results to sup-
port our approach. The applied results are obtained from illustrating our framework
on the dataset from an RCT in severe malaria. We also pay particular attention to
the internal risk model approach for TEH discovery which we show is a particular case
of our method and we point to improvements over current implementation.
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1 Introduction
Randomised control trials (RCTs) are considered to be the most reliable means of com-
paring the effects of multiple treatments or health interventions, sometimes including a
control group (placebo or no treatment). It is increasingly common to exploit the op-
portunities to conduct retrospective treatment interaction analysis (TIA)1 on predictor
variables in RCT data [1]. In such cases, the expected effect of a treatment is dependent
on the value of one or more predictor variables, for example if the effect of a treatment
varies with the age of the subject. Improvement in the volume of measurements obtain-
able from each patient (e.g. genomic profiling) leads to a myriad of candidate factors for
interaction analysis. Given the large costs associated with clinical trials, there is a natural
desire to learn from the data as much as possible. However, statistical power is not free
and any treatment interaction analysis is certainly not immune from false positive rates.
These are the problems that underlay many challenges of performing a valid interaction
analysis. Our motivating example arises from a severe malaria trial, SEAQUAMAT [2],
where investigating the treatment effect heterogeneity can provide valuable insight on
the mechanism of the disease. Moreover, if the utility of a treatment composes of other
factors (e.g. costs, side effects etc) additional to the treatment effect, then information
on treatment effect heterogeneity can help us make better decisions on medical resource
management.
Clearly the power to detect an effect modifier is less than that to detect an overall
treatment effect for an equivalent effect size [3, 4, 5, 6]. In addition, for most interaction
analyses the original trial will have been designed to detect an overall main treatment
effect without tests for interactions taken into consideration [7, 8, 9]. This can contribute
to a lack of power for discovery unless the interaction is larger in magnitude than that
assumed for the main effect in the study design [1], as for subgroups that benefit from a
change in treatment the relative population size is smaller by definition.
If a large number of interaction tests are conducted, the study can also suffer from
spurious false positives arising from multiple comparisons [10, 11, 6]. On the other hand,
false negatives arise due to inadequate power to withstand correction for multiple testing
[11, 6]. If the measurement covariates are dependent, further power can be lost when
testing each variable interaction one at a time rather than in a joint analysis [5, 11].
1Such analyses also go under the name of treatment effect heterogeneity (TEH) or treatment effect
modifiers (TEM).
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For the reasons above, several recommendations have been made on such analyses to
increase the reliability of their findings and better investment of statistical power [5, 11,
12, 6]. There is a strong emphasis on a pre-specified analysis plan, wherein the hypotheses
are defined a priori. Of these hypotheses, the primary analyses must be distinguished
from the secondary analyses and several authors suggest that the primary hypotheses be
restricted to a small number (one to two analyses) supported by external theoretical and
empirical evidence.
These recommendations send a common message that an interaction analysis plan
should be formulated with care. Careful expenditure of power also resonates with the
rationale for using a single global test for interaction discovery, which provides a single
p-value against the null hypothesis of “no treatment interactions.” It can be envisaged
that such a test would require tools that can effectively and efficiently learn about the
structure of and the patterns in the entire dataset, which is a challenging task when the
dimension the variable space is high. Machine learning (ML) and AI methods appear to
be promising tools through their ability to learn about the data [13, 14, 15, 16] and there
has been increasing interest in employing machine learning methods in medical sciences
for disease classification, prognosis and prediction [17, 18, 19, 20, 21].
However, the issue remains that a large number of potential stratifying variables leads
to an even larger search space for treatment-variable interactions. Na¨ıve application of ML
approaches fed with many irrelevant variables can lead to high dimensional models that
can substantially diminish the power of a hypothesis test. Careful selection of potential
stratifiers before discovery can therefore improve the power to detect true associations for
a given effect size.
In this article, we present a framework that facilitates the incorporation of ML algo-
rithms for treatment interaction detection in RCT data. We show that it is possible to
use the clinical response (outcome variable) in an initial screening stage to reduce the
number of stratifying variables without inflating the type-I (false positive) error rate at
the interaction stage. In this way the interaction analysis can be applied to a targeted
subspace effectively reducing the multiple comparisons in the search for interactions. The
essence is to prioritise main effects for interaction testing over those covariates showing
no evidence of association with variation in the clinical response. We provide theoretical
results to support our assertion, making use of the randomisation of treatments in the
design. Hence ML algorithms can informatively guide the interaction detection in order
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to achieve more careful expenditure of power, while ensuring that the false positive rate
is controlled in a rigorous manner.
It has been proposed to use an internally developed risk model to discover TEH in
RCT data [22] and it has been applied to retrospective analysis of TEH in several large
RCT datasets [23]. This approach permits the inclusion of multiple baseline covariates to
construct the internal risk model (IRM). We provide theoretical support for this approach
as it can be considered as a special case of our method. In addition, conventional practice
of the IRM approach for TEH discovery excludes the treatment variable to avoid potential
biases [23]. This is shown to be unnecessary as a consequence of the same mathematical
results that support the validity of our framework. Furthermore, we illustrate that our
framework can provide better resolution of TEH, and how that can be more sensitive to
the TEH signal in certain scenarios.
1.1 South East Asian Quinine Artesunate Malaria Trial (SEAQUA-
MAT)
We demonstrate our TEH detection framework in the context of an analysis of a large
anti-malaria drug trial, SEAQUAMAT [2]. The R notebooks of the interaction analyses
are in the Supporting Information (SI).
SEAQUAMAT is a large randomised clinical trial that compared intravenous quinine
to intravenous artesunate for treatment of severe Plasmodium falciparum malaria. The
trial was conducted at multiple medical centers in Bangladesh, India, Indonesia, and
Myanmar. The findings of this trial provided strong evidence that intravenous artesunate
had superior efficacy than intravenous quinine with one third reduction in mortality.
Severe malaria is a medical emergency with potentially a high rate of case fatality
(10 – 40%), therefore it is of paramount interest to understand how the treatment effect
of artesunate may vary in the patient population even though its superiority of overall
efficacy is well established [24].
2 Screening for evidence of main-effects before testing for
treatment effect heterogeneity
We describe a two-stage approach to interaction discovery whereby in the first stage vari-
ables are ranked by their main-effect strength of association with the outcome response.
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This is followed by an interaction discovery stage using only the K leading covariates
from Stage-1. We show that outcome-driven screening at the first stage does not inflate
the p-values obtained in the second stage testing for treatment interaction and moreover
demonstrates the consistency property.
2.1 Analysis scheme
For ease of exposition we restrict attention to a balanced two-arm clinical trial where indi-
viduals are randomised with equal probability onto a treatment arm A versus a standard-
of-care B.
2.1.1 First stage: prognostic variable screening
We consider an additive generalised linear regression model (GLM) for the clinical out-
come,
E [y] = g (α+XSβ + ITθ +XCβC) , (1)
where y denotes the clinical response for n individuals recruited onto the trial, α represents
an intercept term, the n×p matrix XS contains p interaction-candidate covariates so that
β is a p-dimensional regression coefficient vector. The term IT denotes an indicator binary
vector of the randomised treatment allocations with elements I(i)T = 1 if the i’th individual
received the treatment and I(i)T = 0 otherwise, such that θ captures the causal average
treatment effect. The n × pc matrix XC contains covariates, decided a priori to be
irrelevant to treatment interactions. These could be variables that characterise the trial
procedure (e.g. site of treatment) instead of the patients themselves. The function g (·) is
the link function that performs element-wise operation on the linear predictors.
To screen for main-effects the GLM (1) can be fit to the data to obtain a rank ordered
set of variables, X(r) =
{
x
(r)
1 , ...,x
(r)
p
}
, which is ordered from the most informative
covariate x
(r)
1 to the least informative x
(r)
p . Such ordering could be achieved through
various ways, which we elaborate in section 2.2.1 .
Following this, only the K-leading variables, XSK an n ×K matrix, are selected for
inclusion in the interaction discovery stage. Note that the dimension K should be decided
a priori based on considerations of power, and not using the results of fitting the GLM.
Setting K adaptively based on the evidence in βˆ from the first stage induces p-values that
are not uniformly distributed under H0. Because in that situation the degrees of freedom
(DF) of the test will be subjected to random sampling.
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2.1.2 Second stage: testing for treatment interactions
The selected covariatesXSK can then be tested for treatment interactions via the following
model
E [y] = g (α+ diag(IT)XSKβAK + diag(1− IT)XSKβBK + ITθ + XCβC) , (2)
where diag(IT) is a n × n indicator matrix with 1’s on the diagonal elements where the
corresponding vector IT has a 1, and 0’s elsewhere, so that we have a separate regression
coefficient vector for the treatment group βAK to that of the standard-of-care βBK .
A test for interaction can then be derived by considering the standardised magnitude
of the difference vector
(
β̂AK − β̂BK
)
using a test (e.g. LRT) with a corresponding p-
value that is uniform under the null hypothesis H0 : (βAK − βBK ) = 0 regardless of the
fact that the variable selection in Stage-1 uses information in the outcome-driven βˆ. As
a test such as the LRT provide the single p-value to indicate the evidence for interaction
with treatment, it provides our framework facilitates a global test for detecting TEH.
2.2 On the flexibility of prognostic variable screening
In this section we discuss various possible options for screening prognostic variables in
Stage-1 (section 2.1.1). We begin with single-stage screening procedures (section 2.2.1),
followed by multi-staging screening (section 2.2.2), which is more generalised. We recom-
mend using the multi-stage screening to make the most of supervised and unsupervised
ML algorithms.
2.2.1 Single-stage screening for prognostic variables
We first consider the situation where variable selection is only applied once. Possible
options are:
1. Fitting the full additive model (1), for example in R using glm.R, and then ordering
by the associated p-values assigned to the coefficients.
2. Running a LASSO model [13] and then ranking by the order for which the variables
enter into the LASSO path.
3. Fitting p independent GLMs of the form (1) but where we include only a single
variable (column) of XS at each time. Then ranking covariates by the univariate
p-values assigned to the columns of XS from each model.
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4. Taking principle components (PCs) of XS to form a new basis design matrix X
∗
S
with orthogonal columns made up of the PCs, and then using either option 1. or
option 2. above to rank the leading PC regression coefficients.
Option 1 is only suitable for datasets with a small or moderate number of variables, as
[25] shows that in a logisitc regression, the χ2 distribution is a poor approximation of the
LRT statistic when the number of variables is large in a finite dataset. Option 2 is suitable
for high-dimensional data especially when many of the covariates are not explanatory.
Option 3 is suitable for fast processing of high dimensional data, but because the selection
is based on univariate regressions, it can lose power in the absence of other independent
variables that can help to reduce the noise. Option 3 has a flavour of (univariate) filter
methods for feature selection [26, 27]. All of the options 1–3 do not resolve the problem
of multi-collinearity.
Application of principal component analysis (PCA) in option 4 transforms the covari-
ates into a set of orthogonal basis, it resolves the problem of multi-collinearity. Hence this
option is suitable for datasets having many highly correlated variables, which can occur
when multiple covariates measure the same quantity. Consequently, it enables the appli-
cation of supervised methods that suffer in presence of multi-collinearity (e.g LASSO).
Although tree-based methods such as random forest can cope with multi-collinearity and
therefore their performances are not affected, applying the supervised analysis on the PC
scores can avoid mis-interpretation of variable importance resulted from multi-collinearity.
It is worth noting that PCA is an unsupervised approach to explain the variation in
the covariates. This means that while the most variable PC is the most informative of
the shape of the covariate data cloud, it is not necessarily associated with the outcome of
interest. The advantage of our supervised approach is that it permits the variable selection
to be guided by the outcome. Thus, even if the most variable PCs are approximately noise
variables, our approach is able to give priority to less variable PCs that demonstrate greater
explanatory power.
There is a very interesting connection between our approach and the IRM approach
[22]. The IRM approach first constructs a regression model to explain the outcome by a
set of baseline variables. The treatment is excluded (blinded) and the model is fitted to
the data from both treatment arms (instead of the control arm only).
E [y] = g (α+XSβ) , (3)
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where the mathematical terms are defined the same as in equation 1. For each patient, one
calculates a risk score, which defined by the linear predictor of equation 3. Subsequently,
another regression model is fitted containing the main effect of the treatment, the main
effect of the risk scores and the effect of the interaction between the two. The presence of
TEH is suggested by a significant effect of treatment-risk-interaction.
Like the PC scores, a risk score is also a linear projection of the baseline variables.
If K = 1, option 4 above suggests using a supervised approach to select the most ex-
planatory linear projections provided by PCA. On the other hand, the IRM approach can
be interpreted as selecting the most explanatory linear projection from all possible linear
projections.
There are two important differences between our framework and the IRM approach.
Firstly, the main effect of treatment is included in our framework. The IRM approach
excludes the treatment assignment indicator when developing the IRM due to concerns
with the potential inflation of false positive risk-treatment-interaction. Our mathematical
argument for the validity of our framework also shows that this exclusion is unnecessary.
Secondly, our framework allows the strength of the interaction effect to vary across
the selected variables, whereas in the risk score approach all variables composing the risks
score share the same interaction effect. Our method has the advantage of providing greater
resolution of TEH. Consider the scenario where a (selected) variable has a relatively small
main effect but has major contribution to the effect of the interaction with treatment,
while the variables with dominating main effects do not interact with the treatment. Our
method can detect this signal directly because it models the individual interaction effect
between the treatment and each selected variable. However, the IRM will suffer as the
dominating variables in the risk score will largely determine the shared interaction effect.
Therefore if those dominating variables do not interact with treatment, then the overall
signal of treatment-risk-interaction can be diminished.
2.2.2 Multi-stage ML screening for prognostic variables
If the ML algorithm suggests that there are M variables predictive of the outcome and
M > K, then modelling with the K-leading covariates may not be sufficient and poten-
tially discarding what powerful ML methods can offer. This can be resolved by applying
dimension reduction methods such as PCA to the subset of the covariates that are found
via ML to be predictive of the response. The K-leading PCs will encapsulate the infor-
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mation from the M covariates. Stage-1 can be expanded to have multiple substages of
selection:
1. Substage-I: covariate selection with ML algorithm
(a) An additive model is fitted to the whole dataset via a machine learning method,
e.g LASSO [13, 28, 29], or boosting with stumps [30, 14].
(b) The output of step 1a is used to rank the explanatory power of the variables,
and determines XM, which is an n×M matrix that contains all the variables
predictive of outcome.
2. Substage-II: Selection of PCs
(a) PCA is applied to XM.
(b) To produce XSK , the K-leading PCs can be selected based on their score
variances or the strength of association with y.
The positive integer M can vary from sample to sample as long as K, is pre-defined
given n. This is because the subsetting by ML in Substage-Ib of Stage-1 is independent
of the interaction (to be discussed in section 3 and Web Appendix A). Therefore the DF
is still kept at K for the LRT in Stage-2. Here, the scheme is described with PCA, but it
can be substituted with other (unsupervised) ordination methods.
3 Theory
In order to justify the proposed scheme, it requires to show that the variable selection at
Stage-1 does not influence the findings of interaction detection in Stage-2.
Theorem 1 Let βˆ
(ζ)
denote the standardised MLE of the main covariate effects in an
additive GLM, while (βˆA − βˆB)(ζ) represents the standardised MLE of the difference in
treatment-specific covariate effects in an interaction model with randomised treatments A
and B. Under a null hypothesis of “no difference in covariate effects across treatment
arms”, βˆ
(ζ)
is independent of (βˆA − βˆB)(ζ), such that βˆ(ζ) ⊥ (βˆA − βˆB)(ζ). Hence,
dimension reduction via informative variable selection using βˆ
(ζ)
does not bias the subse-
quent findings of interaction discovery βˆA 6= βˆB.
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Proof: The proof is contained in Web Appendix A. The proof also shows that theorem 1
holds after a linear transformation on the covariates.
In practice, the requirement of prognostic screening at Stage-1 depends on the power
we have in the test for interaction in Stage-2. If there is sufficient power to perform a
global test with all p variables then Stage-1 can be bypassed and therefore K = p.
If the power at Stage-2 is insufficient to include all p variables, then prognostic screening
is performed to select K variables. K should be a deterministic function of n that is
monotonic increasing with no upper bound, such as log(n) or power curve based on n
(but independent of the sampled covariate values X as they vary from sample to sample).
Permitting K to increase with n ensures the consistency of the procedure. That is even
with the worst case scenario where true interaction occurs at the least prognostic variable
xj , as n tends to infinity, K will eventually reach p to include xj . The property of such a
scheme relies on the test in Stage-2 to be consistent, such as the LRT. Theoretically, this
scheme can even withstand the cryptic interactions that leads from βAj 6= βBj but βj = 0.
In section 2.2.2 we have discussed a screening procedure with two substages. In
Substage-I, a chosen supervised approach selects M covariates, XM, based on the evidence
for their prognostic effect. And subsequently in Substage-II, we select the K-leading PCs
of XM from Substage-I.
If the selection of the PCs is based on the ranking of PC score variance, then it is
independent of outcome. Hence the outcome-driven dimension reduction is only executed
in Substage-I to obtain βM, and theorem 1 states this selection does not influence the
subsequent interaction test.
If the PC selection is based on the ranking of their strength of association with the out-
come, then the outcome-driven dimension reduction is performed in both substages. The
covariates XM are selected in Substage-I as above. PCs of XM is a linear transformation.
Since theorem 1 holds after a linear transformation on the covariates, this means that the
PCs of XM can be selected via a supervised approach to obtain XS in substage-II without
biasing the test in Stage-2 that detects the interaction between treatment and XS.
Lets consider all possible linear transformations. Because theorem 1 is stable under
linear transformation, if we select the most prognostic linear combination of the covariates,
it will not induce bias the subsequent interaction test. So a consequence of our proof is
that if the treatment is included in a GLM risk model as in equation 1, it will not inflate
the false positive rate of risk-treatment-interaction. In that case the GLM risk model
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would take the form in equation (1), and the risk score would be defined as XSβ.
In fact, given a set of variables, one can perform any transformation or basis expansion
to generate a new set of bases as the interaction candidates. As long as these operations
do not depend on a function of the treatment indicator, the new set of basis can be
fed into our framework described in section 2.1 without inflating the false positive rate.
This enables the accommodation of non-linearity, and moreover allows the employment of
various powerful ML methods such as boosting [14].
4 Empirical study
We demonstrate our proposed scheme for interaction detection on the RCT dataset from
SEAQUAMAT [2]. Detailed description of the variables and the following analyses are in
the R notebooks in SI.
We first describe the data preparation required for the analysis (section 4.1). Subse-
quently we present the analysis including all the biological variables in the interaction test,
and illustrate its lack of power, which motivates the development of our methodology. As
mentioned in section 2.2, we prefer the multi-stage screening procedure and therefore this
screening procedure is chosen for our primary analyses presented in section 4.3. There we
demonstrate that power can be gained from adopting our framework for TEH discovery.
The full details of the analyses in this section can be found in R notebook S1: Empirical
demonstration of interaction analysis on full malaria trial dataset.
4.1 Pre-process of data
The dataset is first examined to determine any processing required prior to the analysis.
Missing values are imputed by the R package MICE [31] and 50 imputed datasets are
created. The analysis is performed on each imputed dataset to investigate whether the
findings are consistent across imputation variation.
4.2 Interaction analysis with GLM including all variables
In this dataset there are 14 biological variables that serve as interaction-candidates. While
it is understandable that treatment site (country) may have an overall effect, it is not so
intuitive to expect it to interact with treatment. Therefore, country is included in the
model for overall adjustments, but not included as an interaction-candidate.
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We fit the full additive modelM(F)A and the full interaction modelM(F)I . So thatM(F)A
includes the main effect of all variables, whileM(F)I also includes all the interaction terms
between treatment and the 14 biological variables. For each imputed dataset, an LRT
is performed to test whether M(F)A is an adequate approximation of M(F)I . The median
LRT p-value is 0.115 (p-value range = [0.0775, 0.159], 3 s.f.2), only 9 of the 50 imputed
datasets have ANOVA p-values < 0.1. It is apparent that there is no evidence of treatment
interaction in SEAQUAMAT dataset, which may be due to lack of power for testing all
14 variables simultaneously.
4.3 Interaction discovery with PC-GLM after outcome-driven dimen-
sion reduction
After data preparation (section 4.1), we do not observe high correlations among the co-
variates. (Further details are provided in the data preparation section in the R notebook
S1.) Therefore, it is more appropriate to perform the supervised variable selection on the
covariates directly rather than the PCs. This supports our choice of multi-stage screening.
Recall that multi-stage screening divides Stage-1 into substages. Section 4.3.1 describes
Substage-I, where we perform supervised variable selection to subset the variables. Then
in Substage-II, PCA is applied to this subset of variables. We present two variants of this
analysis, where the K-leading PCs are selected based on (i) their variances (section 4.3.2)
and (ii) supervised selection guided by outcome (section 4.3.3).
4.3.1 Supervised screening by the gradient boosting model
To screen the covariates, an additive model is fitted by a gradient boosting model (GBM)
[14, 15] with stumps by using the R package gbm [32]. The covariates are ranked according
to the relative influence (RI) values.
Of the 50 imputed datasets, 37 supports a model with treatment, country and ad-
ditional 10 biological covariates. These biological covariates are consistent cross the 37
imputed datasets and these are coma, logged parasitaemia, age, heart rate, temperature
(◦C), systolic blood pressure, haematocrit, weight, jaundice, duration of fever (days).
2x s.f. is short for rounding to x significant figures.
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4.3.2 Unsupervised PC selection
From the additive model fitted using GBM with stumps in section 4.3.1, we have identified
a subset of 10 biological variables that have the greatest explanatory power in the majority
(37/50) of the imputed datasets. PCA is subsequently performed on this subset and the
PCs are ranked by their PC score variances. Here, we test whether there are differences
in PC effects between treatment groups. Again, for the purpose of demonstrating our
method, we iterate through values of K from 1 to 10 for the LRT in the Stage-2.
The results from testing the interactions between treatment and the leading PCs ex-
hibit a reasonably stable pattern as portrayed in figure 1. There is generally no evidence
of interactions between treatment and the K-leading PCs for DF = K = 1, ..., 5, where all
of the imputed datasets have p-value > 0.1. The number of imputed datasets with p-value
< 0.1 is respectively 47, 50, 50, 50 and 34 for including the leading 6, 7, ..., 10 PCs. The
overall evidence for interactions is strongest when testing for interaction between treat-
ment and the 7 leading PCs. The evidence gradually weakens as more PCs are added,
suggesting the minor PCs are not so informative of TEH.
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Figure 1: The LRT p-values versus degrees of freedom (K) across 50 imputed datasets of
all 1461 patients recruited onto the SEAQUAMAT trial. Here, K represents the number
of most variables PCs included in test for interaction with treatment.
When including the 7 leading PCs in the interaction test, where the median p-value
= 0.0435 (p-value range = [0.0221, 0.0638]) and p-value < 0.05 for 39 of the 50 imputed
dataset. Moreover, figure 2 illustrates that the evidence for TEH is noticeably stronger
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(LRT p-value decreases) for every imputed dataset when we reduce the variables tested
from all 14 biological variables to the 7 PCs representing the 10 variables selected by GBM
(in section 4.3.1).
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Figure 2: Comparison of LRT P-values in a PC-GLM framework for the 1461-patient
SEAQUAMAT data. For every of the 50 imputed dataset, the LRT p-values for TEH are
compared between the analysis with all 14 biological variables and that with the 7 leading
PCs that represent all the variables picked by supervised-variable selection (GBM) in
Substage-I of Stage 1. The purple straight line goes through the origin and has a slope of
1.
There is a notable increase in the strength of evidence for interactions when PC6 is
included to test for interaction with treatment. From inspecting the correlations between
PC6 and biological variables, we find that PC6 is most strongly correlated with jaun-
dice and then systolic blood pressure. Furthermore, jaundice and systolic blood pressure
have the largest absolute PC6 coefficients across all imputed datasets. The signal for in-
teractions attributed to jaundice and systolic blood pressure appears to be captured by
PC6.
The variables identified here, jaundice and then systolic blood pressure, that seems to
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be responsible for TEH, are consistent with the results from the analysis with single-stage
screening (B.1.1 of Web Appendix B), where the evidence for interactions strengthens
when jaundice and systolic blood pressure are added in turn. Comparing figure 2 with
Web Figure B.2 (in Web Appendix B), the power to detect interactions appears to greater
when using multi-stage screening than single-stage screening.
In summary, this analysis clearly demonstrates the how power can be gained after
supervised selection of variables based on the evidence for the main effects without segre-
gation by treatment arms.
4.3.3 Supervised PC selection
For each imputed dataset, an additive LASSO model is constructed to explain the outcome
by the treatment and the PCs obtained in PCA (described in 4.3.2). This provides a
ranking of the PCs by the explanatory power of their main effects. Therefore, K represents
the most explanatory PCs informed by LASSO. To explore the property of this analysis
design, we iterate through values of K from 1 to 10 when performing the interaction test
in Stage-II.
Figure 3 presents the LRT p-values obtained from each imputed datasets for K =
{1, ..., 10}. In general, it appears that the power is the strongest when we include the
K = 2 most explanatory PCs in the interaction test. In this case, 34/50 of the imputed
datasets have LRT p-values <0.05, and 41/50 of those have LRT p-values <0.1. For these
41 imputed datasets, PC6 is found in the K = 2 PCs selected for the interaction test.
This indicates that PC6 is most informative of TEH, which is consistent with the analysis
presented in sections 4.3.2, which indicates that PC6 is most informative of TEH.
The pattern of p-values across K is much more noisy in figure 3 than that in figure
1. This is due to the variation in the LASSO ranking of PCs across imputed datasets.
Once we have included the most two explanatory PCs in the interaction test, inclusion of
additional PCs generally leads to drop of power. This is because, in this case PC6 is most
informative of TEH and it is also (nearly) most explanatory. However, it is important
to note that this phenomenon is not necessarily the case as we have already explained in
section 3 and the proof in Web Appendix A.
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Figure 3: The LRT p-values versus degrees of freedom (K) across 50 imputed datasets of
all 1461 patients recruited onto the SEAQUAMAT trial. Here, K represents the number
of most variables PCs included in test for interaction with treatment.
4.3.4 Supplementary analyses
Aside from the primary analysis presented in section 4.3, we have also performed additional
analyses on the same dataset to further explore our method. These supplementary analyses
are presented in Web Appendix B, containing two sections: B.1 and B.2. In section B.1,
we present a variant of the analysis in 4.3, where we employ single-stage screening instead
of the preferred multi-stage screening. In section B.2, we present the analyses on subsets of
the SEAQUAMAT trial data to investigate the behaviour of our method when the sample
size is substantially reduced.
5 Discussion
In this paper we present a framework that increases the power of interaction discovery
by outcome-driven selection of variables without inflating the type I error rate. Using
the severe malaria trial data as a motivating study for our method, there appears to be
TEH of artesuate. While the interaction test we perform is global, we are still able to
decompose the signal, which suggests that the TEH may be attributed to jaundice and
systolic blood pressure.
Interaction discovery plays a key role in stratified medicine and is a challenging task as
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soon as the number of interaction candidate exceeds a handful of variables. The limited
power for interaction discovery forbids a carpet search for the interaction effects. This
conflicts with the desire to learn as much as possible from the data and stresses the need
for global hypothesis testing tools for interaction discovery. Our novel screening procedure
is fairly flexible and hence can take advantage of powerful ML algorithms. While we
have focused on application to clinical trial data in this paper, our flexible framework
can be applied to datasets from any equivalent randomised experiments for retrospective
exploration of TEH.
ML algorithms themselves lack the statistical rigour required for hypothesis testing.
In spite of this, our mathematical results support the validity of how ML algorithms are
incorporated in our hypothesis testing framework.
In line with the recommendations on interaction analyses that demands hypotheses to
be pre-defined [5, 11, 12, 6], our framework requires determining a priori the degree of
freedom (K) of the test for interaction effect in Stage-2. This is an important reminder
that there is no free power. The decision on the degrees of freedom and the rest of the
analysis would be recorded in a scientific notebook such as an R notebook [33].
In contrast to the strictly hypothesis driven interaction analyses, our framework relaxes
some of the stringencies as it does not require explicit specification of the (few) factors to
be tested. Instead we can initiate with a much larger pool of candidates, and then narrow
it down by variable selection and dimension reduction by ML algorithms. Furthermore,
the highly flexible ML algorithms have much weaker assumptions on the properties of the
underlying random process than traditional methodologies. Therefore it allows the data
to speak for itself.
We found that our approach can be considered as a generalisation of the internal risk
model approach. Because our framework facilitates TEH discovery with finer resolution
by allowing the interactions between the treatment and the variables to be modelled
individually. Therefore it can better detect TEH when the variables driving TEH have
weaker signal for main effect than dominating prognostic variables that do not contribute
to TEH.
The statistical evidence for TEH provided by this method is at the global level and
not for the variables individually. If global signal is decomposed to pin down the potential
set of variables responsible for treatment interaction, it should be treated with caution,
specifically transformation has been applied.
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In our demonstrations, PCA was employed for dimension reduction, which performs a
linear transformation. By examining the PC coefficients or the correlations between the
PCs scores and variables of interest, it allows us to hypothesise which variables interact
with the treatment. However, if there are concerns regarding the interpretability of an
analysis with a transformation, then the user need to design the analysis based on what
is more important.
The user should always use the transformation that is most meaningful to the problem
of interest. If the purpose of the analysis is to purely indicate whether or not there is
evidence for TEH, then the user only need to interpret the LRT p-value, so it might
be more appropriate to choose a transformation that would achieve the most thorough
exploration of the data. However, if the aim of the analysis is to generate hypotheses on
which specific variables contribute to TEH, then they should employ the transformation
(including no transformation) that would be most helpful for deciding which variables to
be tested in future experiments. Of course, there is a trade-off—a simpler analysis would
be easier to interpret but it can potentially miss the complex patterns and hence the signal
in the data. This is one of the examples of “no-free-lunch” in statistical analysis. It is also
important to note that if the user decomposes the global/aggregated interaction signal
to obtain a suggested set of original variables driving the interaction with treatment, the
identification of an interaction between the treatment and a specific variable should be
viewed as hypothesis generation.
Our framework furnishes a more holistic exploration of the data while also provides
rigorous evidence for potential interactions in retrospective interaction analyses. Although
the false positive rate is controlled in our approach, the findings from using this framework
will still need to be replicated in other datasets for validation [5]. However, our method
can assist researchers to decide whether to further invest in exploring the heterogeneous
effect of a treatment.
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Supplementary Materials
A Web Appendix A: Mathematical arguments for theorem
1
In this section, we present the proof that under a null hypothesis, H0, of “no difference in
covariate effects across treatment arms”, in a generalised linear model (GLM) framework,
the standardised MLEs of the coefficients βˆ
(ζ)
in an additive model are (asymptotically)
independent of the standardised MLE difference between the group-specific coefficients,
(βˆA− βˆB)(ζ) in an treatment interaction model, when we have RCT data.
Defining the models and parameters
Let n be the number of individuals, where n = nA + nB, with ng indicating the number
individuals in treatment group g ∈ {A,B}. The n×p matrixXS contains the p interaction-
candidate covariates, that potentially contribute to the interaction effect. In a study, we
might also observe pc covariates, which we do not consider as interaction-candidates. The
n × pc matrix XC holds the pc interaction-irrelevant covariates, whose coefficient values
are “c”ommon across treatment groups. The term 1A and 1B are vectors of length nA
and nB respectively, where all elements equal to 1. On the other hand, 0A and 0B are
the equivalent 0 vectors. The outcome values of all n patients are recorded in the vector
y, and are assumed to have come from a distribution in the exponential family.
For the purpose of the following calculations, the outcome vector and covariate matrices
are arranged such that
y =
 yA
yB
 , XS =
 XA
XB
 , XC =
 XCA
XCB
 , (4)
where yg, Xg and XCg are respectively the outcome vector and covariate matrices of
treatment group g.
Consider a GLM of the following form
E[yi] = g(ηi),
where yi denotes the i
th element of y, g(·) is the link function and ηi is the linear predictor
of the ith observation. The vector η represents the linear predictor for all observations.
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Additive model
To set up the additive model (no interaction), MA we first construct the data matrix D
as
D =
 XA 1A 0A XCA
XB 0B 1B XCB
 . (5)
This column arrangement has been selected because our primary interest is in the interaction-
candidate covariates. The linear predictor of the additive GLM is defined as
η = Xγ,
X = D, (6)
where the coefficient vector γ can be decomposed into γ = (β, βA0, βB0,βC). The β is a
vector the p pooled main effects of the interaction-candidates, while βC is the correspond-
ing vector for the pc interaction-irrelevant covariates. The term βg0 is the intercept of
treatment group g ∈ {A,B}. The matrix X appears redundant here, however, having this
‘wrapper’ matrix enables more flexible construction of the linear model as we demonstrate
in a later section on PC-GLM.
Interaction model
To construct the interaction model, MI(1), the matrix D is expanded subsequently to
obtain
D(1) =
 XA 0nA×p 1A 0A XCA
0nB×p XB 0B 1B XCB
 , (7)
where D(1) is a n× (2(p+ 1) + pc) matrix and 0l1×l2 is a l1 × l2 zero matrix.
The linear predictor of a full interaction model with treatment can be constructed as
η = X(1)γ(1),
X(1) = D(1). (8)
The coefficient vector γ(1) is defined as γ(1) =
(
βA,βB, β˜A0, β˜B0, β˜C
)
. The vector βg
is the treatment-specifc coefficients of the interaction-candidates for treatment group g ∈
{A,B}. The terms β˜A0, β˜B0 and β˜C are equivalent to βA0, βB0 and βC respectively.
In preparation of an alternative construction, the columns of D(1) are re-arranged to
obtain:
X(2) =
 0nA×p XA 0A 1A XCA
XB 0nB×p 1B 0B XCB
 . (9)
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With this matrix, the linear predictor of an alternative interaction model, MI(2), is set
up according to
η = X(2)γ(2),
X(2) = D(2). (10)
where the coefficient vector γ(2) =
(
βB,βA, β˜B0, β˜A0, β˜C
)
. Note that MI(1) and MI(2)
have the same column space, and hence their respective coefficient vectors are composed
of the same set of elements.
In this case, it is observed that the matrix X can be defined in terms of linear projec-
tions of X(1) and X(2), according to
X = X(1)J(1)
= X(2)J(2), (11)
with
J(1) =

Ip 0p×(pc+2)
Ip 0p×(pc+2)
0Tp 1 0 0
T
pc
0Tp 0 1 0
T
pc
0pc×(p+2) Ipc

, J(2) =

Ip 0p×pc+2
Ip 0p×pc+2
0Tp 0 1 0
T
pc
0Tp 1 0 0
T
pc
0pc×(p+2) Ipc

,
where both J(1) and J(2) are (2(p+ 1) + pc)× (p+ pc + 2). The notation Id represents a
d× d identity matrix. The expression 0d is a d-dimensional zero vector, while 0d1×d2 is a
d1 × d2 zero matrix.
Calculations
We first demonstrate βˆ ⊥ βˆA−βˆB, which can be used to argue that βˆ(ζ) ⊥ (βˆA − βˆB)(ζ)
as n→∞. The MLEs of γ, γ(1) and γ(2) are respectively γˆ, γˆ(1) and γˆ(2). Asymptoti-
cally, γˆ follows a multivariate normal distribution, γ ∼ Np+pc+2(γ,Σ), with the variance-
covariance matrix Σ. Similarly, γˆ(1) ∼ Np′(γ(1),Σ(1)), with p′ = 2p+pc+2. As γˆ(1)−γˆ(2)
is a linear transformation of γˆ(1), the difference vector also follows a normal distribution,
albeit only having 2p dimensions. This is due to the zeros in the last pc + 2 elements of
γˆ(1) − γˆ(2).
We use the notation Mr1:r2×c1:c2 to refer to the sub-matrix from rows r1 to r2 and from
columns c1 to c2 of the original matrix M . The covariance matrix Cov
(
βˆ, βˆA − βˆB
)
is
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located in the sub-matrix Cov
(
γˆ, γˆ(1) − γˆ(2)
)
1:p×1:p
. By the properties of normal random
variables, Cov(γˆ, γˆ(1) − γˆ(2))1:p×1:p = 0p×p implies βˆ and βˆA − βˆB are independent.
The MLEs of GLM coefficients are often computed using the iteratively re-weighted
least squares (IRLS) algorithm. The estimates of γ, γ(1) and γ(2) respectively take the
form
γˆ =
(
XTWˆX
)−1
XTWˆz,
γˆ(1) =
(
XTWˆ(1)X
)−1
XTWˆ(1)z(1),
γˆ(2) =
(
XTWˆ(2)X
)−1
XTWˆ(2)z(2),
Wˆ is the MLE estimate of W , which is an n × n diagonal matrix, and the ith diagonal
element, wi, is the weight of the i
th individual given the data and model parameters. zˆ
denotes the MLE the n-dimensional vector z, which is the working dependent variable
given the data and model parameters. In the interaction models, MI(1) and MI(2), the
terms Wˆ (1), Wˆ (2), zˆ(1) and zˆ(2) are defined similarly.
The covariate matrix Cov
(
γˆ, γˆ(1) − γˆ(2)
)
can be expressed as
Cov{(XTŴX)−1XTŴz,(
XT(1)Ŵ (1)X(1)
)−1
XT(1)Ŵ (1)z(1) −
(
XT(2)Ŵ (2)X(2)
)−1
XT(2)Ŵ (2)z(2)} (12)
Since X(1) and X(2) have the exact same set of column vectors, we have Wˆ (1) =
Wˆ (2) = W˜ and z(1) = z(2) = z˜. We can then rewrite equation (12) as(
XTŴX
)−1
XTŴCov (z, z˜) W˜X(1)
(
XT(1)W˜X(1)
)−1−(
XTŴX
)−1
XTŴCov (z, z˜) W˜X(2)
(
XT(2)W˜X(2)
)−1
=Q
[
W˜X(1)
(
XT(1)W˜X(1)
)−1 − W˜X(2) (XT(2)W˜X(2))−1]
=Q
(
XXT
)−1
X
[
XTW˜X(1)
(
XT(1)W˜X(1)
)−1 −XTW˜X(2) (XT(2)W˜X(2))−1] ,
(13)
whereQ =
(
XTŴX
)−1
XTŴCov (z, z˜). This can be further simplified by substituting
equation (11) into equation (13), leading to
Q
(
XXT
)−1
X
(
JT(1) − JT(2)
)
. (14)
Because the first p columns of JT(1)−JT(2) are zero columns, so are those in the matrix
Cov
(
γˆ, γˆ(1) − γˆ(2)
)
and hence Cov
(
βˆ, βˆA − βˆB
)
is a zero matrix.
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When the underlying model is correct, as n→∞, the MLE of a parameter approaches a
normal distribution and its standard error approaches the asymptotic standard deviation
of the estimator. Consequently, a standardised MLE will be asymptotically normally
distributed. Therefore, the zero-covariance property is again a sufficient condition for
independence. Let γˆ(ζ) and (γˆ(1) − γˆ(2))(ζ) denote the standardised MLEs of γˆ and
γˆ(1)− γˆ(2) respectively.
The covariance matrix of the standardised MLEs is
Cov
(
γˆ(ζ), (γˆ(1) − γˆ(2))(ζ)
)
= diag(SEγˆ)
−1Cov
(
γˆ, γˆ(1) − γˆ(2)
)
diag(SEγˆ(1)−γˆ(2))
−1,
where diag(v) is a diagonal matrix with ith diagonal value equal to the ith element of some
vector v. The ith element of the vector SEγˆ is the standard error of the i
th element of γˆ.
The standard error vector SEγˆ(1)−γˆ(2) for γˆ(1) − γˆ(2) is similarly defined.
As the first p columns of Cov(γˆ, γˆ(1) − γˆ(2)) are zero vectors, the so that those in
Cov
(
γˆ(ζ), (γˆ(1) − γˆ(2))(ζ)
)
. Consequently, Cov
(
βˆ
(ζ)
,
(
βˆA − βˆ′B
)(ζ))
is a zero matrix,
which satisfies the independence condition required in theorem 1.
Extension to GLM with linear projections of baseline covariates
In this section we present an extension of the proof to accommodate GLM with linear
projections of baseline covariates. The columns of the p× q matrix V are the weights for
the baseline covariates. To perform a regression on the projected variables, XA and XB
are first projected by V . As a result of the projection, the matrices X, X(1) and X(2)
will need to be re-defined. The matrix X of the additive model, MA, is now written as a
linear projection of D in equation (5):
X = DU =
 XAV 1A 0A XCA
XBV 0B 1B XCB
 with U =
 V 0p×(pc+2)
0(pc+2)×p I(pc+2)×(pc+2)
 ,
(15)
where the dimensions of matrix U are (p + pc + 2) × (p + pc + 2). The covariate matrix
X(1) of the interaction model, MI(1), becomes
X(1) = D(1)U (1) =
 XAV 0nA×p 1A 0A XCA
0nB×p XBV 0B 1B XCB

U (1) =

V 0p×p 0p×(pc+2)
0p×p V 0p×(pc+2)
0(pc+2)×p 0(pc+2)×p I(pc+2)×(pc+2)
 , (16)
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where D(1) is defined in equation (7). The square matrix U (1) has 2p+pc+ 2 dimensions
on each side. Similarly, the covariate matrix X(2) of the interaction model, MI(2), is a
linear projection of D(2) by U (2):
X(2) = D(2)U (2) =
 0nA×p XAV 0A 1A XCA
XBV 0nB×p 1B 0B XCB

U (2) =

0p×p V 0p×(pc+2)
V 0p×p 0p×(pc+2)
0(pc+2)×p 0(pc+2)×p I(pc+2)×(pc+2)
 , (17)
where D(2) is defined in equation (9) and the square matrix U (2) has the same dimensions
as U (1).
Substituting the new definitions ofX, X(1) andX(2) described in equations (15), (16)
and (17) respectively into the covariance expression in equation (12), and then following
the same arguments and workings from there onwards, we will also arrive at equation (14).
Therefore, the proof also holds for GLM with linear projections of baseline covariates.
In the case of PC-GLM, q = p and the columns of V are the PC coefficients of XS
defined in equation (4). On the other hand, in the unblinded IRM approach, q = 1 and
V is a vector containing the coefficients for the main effects of XS in the risk model.
B Web Appendix B: Supplementary analyses of the SEAQUA-
MAT trial data
In this section, the first part (B.1) presents the analyses on the data contain all 1461
patients in the trial, where we apply single-stage screening of prognostic variables. This
and the primary analysis (in section 4.3) allow the comparison between single-stage and
multi-stage screening.
In the second part (section B.2), we subsample the SEAQUAMAT data so the subsets
only contain 600 patients. We then apply the multi-staging screening as in section 4.3.
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B.1 Analyses with all patients recruited in the trial
B.1.1 Interaction discovery with GLM after outcome-driven dimension re-
duction
As the purpose of this demonstration is to showcase the properties of our approach, we
iterate through K values from 1 to 10. The LRT p-values are presented in figure B.1.
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Web Figure B.1: The LRT p-values versus degrees of freedom (K) across 50 imputed
datasets of all 1461 patients recruited onto the SEAQUAMAT trial. Here, K the number
of PCs of the variables selected by supervised variable selection at substage-II of Stage-1
of the interaction analysis.
Across the different K values, the evidence is the strongest when we test for the inter-
action between treatment and the set of 6 variables = {coma, logged parasitaemia, age,
heart rate, temperature, systolic blood pressure}. The interaction with this set provides
a median p-value = 0.0787 (p-value range = [0.0460, 0.105], 3 s.f.) and p-values < 0.1
are obtained from 48 of the 50 imputed datasets. Moreover, figure B.2 illustrates that the
evidence for TEH is stronger (LRT p-value decreases) for every imputed dataset when we
reduce the variables tested from all 14 biological variables to the 6 variables selected by
boosting.
As depicted in figure B.1, further inclusion of the remaining biological candidates
displayed some instability. When the haematocrit variable is added to this set, the strength
of evidence for interaction effect experiences a considerable drop with only three imputed
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Web Figure B.2: Comparison of LRT p-values in a GLM framework for the 1461-patient
SEAQUAMAT data. For each of the 50 imputed dataset, the LRT p-values for TEH are
compared between the analysis with all 14 biological variables and that with 6 biological
variables selected by GBM in Stage-1. The purple straight line goes through the origin
and has a slope of 1.
datasets having p-value < 0.1. Subsequent inclusion of weight reduces to only one imputed
dataset with p-value < 0.1. However, inclusion of jaundice pushes the number of datasets
with p-value < 0.1 up to 42 but adding on duration of fever leads to a reduction to 34 sets
with p-value < 0.1.
In summary, even though the strength of evidence is not as strong a the multi-stage
analysis, it is observed that the power to detect interactions can be increased by single-
stage screening of the main effects in the additive model.
B.2 Analyses only with patients having staging data
The full details of the analyses in this section can be found in R notebook S2: Empiri-
cal demonstration of interaction analysis on the data of the subset of patients from the
SEAQUAMAT trial who have staging information.
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Of the 1461 patients in the SEAQUAMAT trial, 854 have staging data of the malaria
parasite lifecycle. The data is in the form of percentages of the following stages: tiny
ring, small ring, large ring, early troph, mid troph, late troph and gametocytes. There are
another two additional variables in this dataset, which are base deficit and indication of
prior antimalarials treatment received.
The purpose of this section is to demonstrate that when the sample size of the SEAQUA-
MAT trial data is substantially reduced, that our framework can still achieve better power
to detect TEH than na¨ıvely including all the variables in the interaction test, even when we
account for subsampling variation. Section B.2.1 presents the problem encountered when
including all biological variables in the interaction analysis on the 854 patients. Section
B.2.2 describes the subsampling of the SEAQUAMAT data, so that the problem in section
B.2.1 will have a greater impact and that we can account for subsampling variation. Sub-
sequently, we apply our framework to each subset and present the results in section B.2.3.
Here, we only consider multi-stage screening, which is our primary recommendation. In
addition, we select the PC in Substage-II by its variance as that seems to exhibit more
stable behaviour (section 4.3.2).
B.2.1 Interaction discovery with GLM including all variables
After the inclusion of all the aforementioned additional variables, the degrees of freedom
of the LRT test for interaction reaches 25, with 30 and 55 variables respectively in the full
additive and the full interaction model. Given the results presented by [25], it is reasonable
to question the accuracy of the LRT p-value of the interaction test. To investigate the bias,
we simulate distribution of the LRT p-values under H0, and this simulated distribution is
presented in figure B.3, which clearly displays the underestimation of p-values.
Using the simulated distribution to correct for the observed bias, the full interaction
test for TEH provides a p-value of 0.574 (3 s.f.), which is a borderline result that does not
provides evidence against the global H0 of no interactions at the 5% confidence level.
B.2.2 Sub-sampling
While the result with the 854 patients is not statistically significant at the 5% level, the
LRT p-value is rather close to the 0.05 threshold. Therefore we subsample the data to 600
patients where there would be less power to detect TEH.
We have created 100 subsampled datasets. As the SEAQUAMAT trial data is roughly
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Simulated LRT p−value for TEH under the H0 given the 
SEAQUAMAT data with staging information (n = 854)
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Web Figure B.3: The simulated distribution of LRT P-values for TEH under the H0 given
the SEAQUAMAT trial data with staging information (sample size = 854).
balanced between the two treatment arms, the subsampled data subsampling is by strat-
ified treatment arms. For each subsample, we have simulated the LRT p-value distribu-
tion for H0 including all 25 biological interaction-candidates. The LRT p-value for full
treatment interaction of each dataset is corrected using the corresponding simulated H0
distribution. We focus only on the 67 subsamples that have (corrected) LRT p-values
greater than 0.1.
B.2.3 Interaction discovery with PC-GLM after outcome-driven dimension
reduction
Each of subsampled dataset is fitted with GBM with stumps. Relative influence is used to
determine the priority of variable inclusion for testing the global TEH. For each subsample,
there is still a fairly large number of variables with that have positive relative influence,
where many of these variables have very low relative influence (<1), so they are likely to
have little predictive information and we only select the variables with RI >1. Following
this, PCA is applied to the variables selected for each subsampled dataset.
Because we have already performed the analysis on the full 1461-patient dataset with a
range of K values (section 4.3), we will not do the same here. Instead we chose the 8 most
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variable PCs to include in the LRT to test whether they interact with the treatment. We
chose 8 because of the 67 subsets, the mininum number of variables with RI greater than
1 is 8, suggesting that when we account for subsampling variation, there are at least 8
variables that are informative of prognosis. To protect from potential poor approximation
by the χ2 distribution used in the LRT, the null distribution of the LRT p-values are
simulated and used to correct the LRT p-values for the interactions between the 8 leading
PCs and the treatment.
It is evident in figure B.4, we improved power to detect TEH when we reduce the
variables tested from 25 biological variables to 8 PCs representing the baseline covariates
selected by GBM. Fifty-seven of the 67 subsamples have improved in the strength of evi-
dence for TEH. The strength of evidence for TEH varies considerably because subsampling
patients will creates variation in the signal of TEH across the subsampled datasets. Nev-
ertheless, the general trend is that our framework can have better power to detect TEH
than including all variables.
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Web Figure B.4: LRT P-values comparison in a PC-GLM framework for subsamples of
SEAQUAMAT data with staging information (n=600). For every of the 67 subsampled
dataset, the LRT p-values for TEH are compared between the analysis with all 25 biological
variables and that with 8 major PCs representing all the variables with relative influence >
1 indicated by supervised-variable selection (GBM). The purple straight line goes through
the origin and has a slope of 1.
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